

1 Causal associations between plasma proteins and prostate cancer: a 2 Proteome-Wide Mendelian Randomization

3 Chen Lin^{1#} , Rong Zhuona^{1#} , Gu Yanlun^{1,2} , Chen Yuke³ , Yu Wei³ , Zhou Ying^{1*} ,
4 Pang Xiaocong^{1*}

5 ¹Department of Pharmacy, Peking University First Hospital, Xishiku Street, Xicheng
6 District, 100034 Beijing, China

7 ^{1,2}School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Haidian
8 District, 100191 Beijing, China

9 ³Department of Urology Surgery, Peking University Third Hospital, Xueyuan Road
10 38, Haidian District, 100191 Beijing, China

11 *Corresponding author.

12 #Contributed equally.

13 Abstract

14 Background:

15 Due to the limitations in specificity of current diagnostic methods for prostate cancer
16 (PCa), more reliable biomarkers are needed to explore for improving early detection.
17 Plasma proteins represent a promising source of biomarkers, therefore understanding
18 the causal relationships between specific plasma proteins and PCa could be
19 conducive to identify novel biomarkers and therapeutic targets for PCa prevention
20 and treatment.

21 Methods:

22 We performed a meta-analysis of two independent genome-wide association studies

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 (GWASs) including 94,397 individuals with PCa and 192,372 controls. A mendelian
24 randomization (MR) supplemented by colocalization analysis was conducted, using
25 *cis*-acting variants on 4,907 plasma proteins from deCODE Genetics (N=35,559) and
26 2,940 plasma proteins from UK Biobank Pharma Proteomics Project (UKB-PPP)
27 (N=54,219). Then, the biological pathway analysis and druggability evaluation of the
28 risk proteins were further performed.

29 **Results:**

30 Five possible susceptibility loci (JAZF1, PDILM5, WDPCP, EEFSEC, and TNS3) for
31 PCa were identified through the meta-analysis of GWASs. Among 3,722 plasma
32 proteins, 193 proteins were associated with PCa risk, of which 20 high-risk proteins,
33 including KLK3, were validated in both the deCODE and UKB-PPP cohorts.
34 Functional annotation of these genes encoding proteins confirmed enrichment of
35 immune response, inflammatory response, cell-cell interaction and so on. Genetic
36 colocalization and druggable genome analyses also identified several potential drug
37 targets for PCa, such as HSPB1, RRM2B and PSCA.

38 **Conclusions:**

39 We identified novel variants as well as several protein biomarkers linked to PCa risk
40 and indicated pathways associated with PCa, which offered new insights into PCa
41 etiology and contributed to development of novel biomarkers for early detection and
42 potential therapeutic interventions.

43 **Funding:**

44 This work was supported by grants from Beijing Municipal Natural Science

45 Foundation (grant No. JQ24059, No. L234038) and National Natural Science

46 Foundation of China (grant No. 82274015).

47 **Keywords:** Prostate cancer, Proteins, Biomarkers, Mendelian randomization,

48 Colocalization analysis

49 **Graphical abstract:** A comprehensive study design summarized as follows.

50 **Introduction**

51 Prostate cancer (PCa) is the second most common malignancy with an estimation of
52 1.5 million new cases in 2022, which is account for 14% of total cancer diagnosed in
53 men worldwide(Ferlay J, 2024). Even more worrying is that the number of new cases
54 of PCa are projected to 2.9 million by 2040(James et al., 2024). Despite
55 advancements in medical technology, early detection of PCa remains a significant
56 challenge due to the limitations in specificity of current diagnostic methods, such as
57 prostate-specific antigen (PSA) testing(Carter et al., 2013; Draisma et al., 2009;
58 Oesterling, 1991). Therefore, there is an urgent need for more accurate and reliable
59 biomarkers that can improve early detection and prognostic evaluations of PCa.

60 Plasma proteins have key roles in the development and progression of PCa, such as
61 interleukin (IL)-6(Deichaite et al., 2022), insulin-like growth factor (IGF)-1 and IGF-
62 binding protein (IGFBP)-1(Cao et al., 2015). However, observational studies
63 exploring the association between plasma proteins and PCa risk are often limited by
64 confounding factors and selection bias, making it challenging to establish a clear
65 causal relationship.

66 To overcome these limitations, Mendelian randomization (MR) offers a robust
67 methodological approach. This approach utilizes the principle of random assortment
68 of genes from parents to offspring, using genetic variation as an instrumental variable,
69 which mimics the randomization process in a controlled trial, thereby minimizing the
70 impact of reverse causality(Davies, Holmes, & Smith, 2018). With the recent
71 development of proteomics technology, several large-scale proteomic studies have

72 identified over 18,000 protein quantitative trait loci (pQTLs) covering more than 4800
73 proteins(Ferkingstad et al., 2021; Pietzner et al., 2021). By using MR, researchers can
74 gain a deeper comprehension of whether particular plasma proteins hold a causal
75 nexus with PCa, thereby potentially unraveling novel biomarkers and targets for the
76 prevention and treatment of PCa.

77 In this study, we performed a meta-analysis of two genome-wide association studies
78 (GWAS) on PCa (PRACTICAL and FinnGen) for a total sample size of 94,397 cases
79 and 192,372 controls. Based on GWAS summary statistics data from deCODE and
80 UKB-PPP cohorts, we further performed a protein-wide MR (PW-MR) study,
81 supplemented by colocalization analysis, to explore the casual relationship between
82 plasma proteins and PCa risk. Moreover, we indicated biological processes and
83 pathways associated with PCa, and evaluated the druggability of risk proteins. We
84 aimed to identify novel plasma proteins biomarkers for PCa, which could address the
85 limitations of current diagnostic methods and offer new insights into the biological
86 mechanisms of PCa and potential therapeutic targets for intervention.

87 **Results**

88 **Meta-analysis of the Genome-Wide Association Studies for Prostate Cancer**

89 We conducted a meta-analysis combining two GWAS studies with a collective sample
90 size of 94,397 individuals with PCa and 192,372 controls, aiming to identify genetic
91 variants linked to PCa. The associations and assessment of SNPs heterogeneity that
92 passed the genome-wide P-value threshold at these loci with PCa were presented in
93 Supplementary Table 1. We found 5 genetic risk loci contained at least one SNP
94 passing the genome-wide significance threshold of $P \leq 5 \times 10^{-8}$: JAZF1, PDILM5,
95 WDPCP, EEFSEC, and TNS3 (Figure 1). Among them, PDLIM5, WDPCP, EEFSEC
96 and TNS3 were promising candidates as novel susceptibility loci associated with PCa.
97 Supplementary Figure 1 displayed the associated quantile-quantile plot. The
98 LocusZoom plots of the top SNPs at JAZF1, PDILM5, WDPCP, EEFSEC and TNS3,
99 along with their genomic location, GWAS P values and recombination rate with
100 neighboring SNPs were visualized in Supplementary Figure 2. In summary, this
101 GWAS meta-analysis discovered genetic variations in one recognized PC-associated
102 loci and four potential novel loci, providing a reliable dataset for MR analyses.

103 **Cross-phenotype Analysis of Prostate Cancer**

104 We used the iCPAGdb to conduct the cross-phenotype genetic association analyses
105 with PCa genome-wide significant SNPs ($P \leq 5 \times 10^{-8}$). The iCPAGdb offered an
106 improved algorithm for identifying cross-phenotype associations by using pre-
107 computed ancestry-specific LD databases and integrating genetic data from 3793
108 traits in the NHGRI-EBI GWAS catalog(L. Wang et al., 2020). After adjusting for

109 Bonferroni's correction, the cross-phenotype analysis indicated that 117 traits showed
110 significant association with PCa (Supplementary Table 2). As shown in Figure 2, the
111 top 10 enrichments were for prostate specific antigen measurement ($P=7.16\times 10^{-43}$),
112 body height ($P=2.18\times 10^{-30}$), BMI-adjusted waist-hip ratio ($P=1.32\times 10^{-26}$), high
113 density lipoprotein cholesterol measurement ($P=2.38\times 10^{-22}$), systolic blood pressure
114 ($P=2.93\times 10^{-22}$), balding measurement ($P=3.01\times 10^{-22}$), leukocyte count ($P=3.46\times 10^{-21}$),
115 blood protein measurement ($P=4.95\times 10^{-21}$), body mass index ($P=1.71\times 10^{-20}$) and
116 heel bone mineral density ($P=2.02\times 10^{-19}$).

117 **Proteome-Wide Mendelian Randomization Studies of Prostate Cancer**

118 The genetic association summary statistics of 35,559 Icelanders from deCODE
119 Genetics and 54,219 Europeans from the UKB-PPP were utilized to investigate the
120 relationship between PCa and plasma proteins. Our genetic instrument selection
121 strategy enabled us to examine 1778 and 1944 proteins from deCODE and UKB-PPP
122 (Supplementary Table 3A and B). Using the Wald ratio or IVW method, a total of 193
123 unique plasma proteins were significantly associated with PCa after multiple tests
124 with a 5% FDR correction. This analysis yielded 137 proteins in UKB-PPP more than
125 76 proteins in deCODE (Figure 3A). The results of Heterogeneity test based on Q
126 statistics showed little evidence of heterogeneity. Furthermore, no significant
127 intercept was detected, implying that there was no directional pleiotropy observed.
128 After FDR correction, 20 proteins were detected in both data sets and the identified
129 associations were consistent (Figure 3B). Genetic prediction indicated that 11 of these
130 20 proteins were positively associated with the risk of PCa as well as remaining 9

131 proteins were negatively associated, suggesting that these 9 proteins maybe protective
132 factors against PCa (Supplementary Table 4). A PhenoGram depicted the
133 chromosomal location of the 193 unique identified proteins in deCODE and UKB-
134 PPP studies (Figure 3C).

135 **Colocalization analysis**

136 We performed colocalization analyses of proteins significantly expressed in deCODE
137 and UKB-PPP studies with PCa. It was observed that 4 proteins in deCODE study and
138 7 proteins in UKB-PPP were colocalized with PCa associations with high support of
139 evidence ($PPH4 \geq 0.8$) (Table 1), suggesting that these 10 plasma proteins might serve
140 as potential targets for treating PCa. Among them, SERPINA3 showed strong
141 colocalization evidence in both decode ($PPH4=0.952$) and UKB-PPP ($PPH4=0.951$)
142 studies. This analysis identified 1 causal variant in deCODE (rs61976125) and 1
143 causal variant in Fenland (rs6575449) (Figure 4).

Table 1. Analysis of Mendelian randomization and colocalization of significant proteins with PCa.

GWAS	Outcomes	Proteins	Mendelian randomization			Colocalization
			OR (95%CI)	P value	P value after FDR adjustment	Analysis PH4
deCODE	Prostate Cancer	MSMB	0.86(0.84,0.88)	1.56E-27	2.82E-24	0.999
		POGLUT3	0.89(0.83,0.96)	1.16E-03	2.44E-02	0.998
		PRSS3	0.93(0.91,0.94)	1.00E-18	6.03E-16	0.956
		SERPINA3	1.11(1.06,1.15)	7.18E-08	1.05E-05	0.952
UKB-PPP	Prostate Cancer	USP28	0.47(0.40,0.56)	7.27E-17	2.89E-14	0.999
		KLK3	9.70(4.94,19.03)	3.83E-11	6.91E-09	0.999
		IGFBP3	1.07(1.05,1.09)	2.04E-11	4.49E-09	0.997
		CASP10	1.22(1.11,1.34)	4.73E-05	1.54E-03	0.988
		HDGF	0.96(0.95,0.97)	2.61E-17	1.29E-14	0.966
		SERPINA3	1.10(1.07,1.13)	1.64E-10	2.32E-08	0.951
		C5	1.19(1.11,1.27)	5.32E-07	4.06E-05	0.883

146 **Gene-Based Association and Pathway Analyses**

147 We used the GENE2FUNC tool available in FUMA to explore the biological
148 significance, functional implications and tissue-specific expression of the genes
149 identified from our GWAS. These genes appeared to be significantly enriched in
150 inflammatory and immune pathways (such as defense, immune and inflammatory
151 response), as well as cell interaction and signaling pathways (such as interaction
152 between organism and cell adhesion) (Figure 5A). The KEGG pathway enrichment
153 analysis revealed several pathways that were significantly enriched, such as cytokine-
154 cytokine receptor interaction, p53 signaling pathway, JAK-STAT signaling pathway,
155 pathways in cancer and apoptosis (Figure 5B). These analyses indicated potential
156 biological processes and mechanisms associated with PCa. The 193 unique genes
157 were predominantly expressed in the lymphocytes, blood, liver and prostate
158 (Supplementary Figure 3).

159 **Druggability of identified proteins**

160 Exploring new therapeutic opportunities for PCa based on genetic information is
161 crucial for developing targeted treatments. In our study, we examined the druggability
162 of genes and proteins identified in MR analyses using OpenTargets databases. We
163 investigated 128 unique drugs targeting 45 identified proteins (Supplementary Table
164 5). Among these, three drugs (APATORSEN, TRIAPINE and MK-4721) currently in
165 clinical trials were intended for PCa treatment, with each targeting HSPB1, RRM2B
166 and PSCA, respectively. Notably, the effects of these drugs on their respective protein
167 targets align with the directions indicated by our MR results, suggesting a consistency

168 between genetic evidence and therapeutic potential. In addition, several other
169 identified targets, such as RET, FGFR3, NCAM1, TYMP, TNFRSF10B, MMP3,
170 TACSTD2 and NOTCH2, were implicated in various cancers and present potential
171 therapeutic avenues.

172 **Discussion**

173 In this study, we conducted a comprehensive meta-analysis of two GWAS for PCa,
174 identifying significant genetic loci associated with PCa risk. The combined sample
175 size of 94,397 cases and 192,372 controls revealed one known (JAZF1) and four
176 potential novel (PDLIM5, WDPCP, EEFSEC and TNS3) susceptibility loci of PCa.
177 JAZF1 (Juxtaposed with another zinc finger gene 1) is a transcriptional repressor of
178 testicular nuclear receptor 4 (TR4) (Nakajima, Fujino, Nakanishi, Kim, & Jetten,
179 2004). Several GWAS studies have implicated that JAZF1 is highly associated with
180 type 2 diabetes and PCa risk(Frayling, Colhoun, & Florez, 2008; Machiela et al.,
181 2012; Saxena, Voight, Zeggini, Scott, & Genetics, 2008; Thomas et al., 2008). JAZF1
182 may influence the risk of PCa through its role in metabolic regulation(Rosario et al.,
183 2023) and cellular proliferation(Sung et al., 2018).

184 PDLIM5 (PDZ and LIM domain 5) is a member of the enigma subfamily and features
185 a N-terminal PDZ domain and three C-terminal LIM domains(X. J. Wang & Su,
186 2010). A study implicated that downregulating the expression of PDLIM5 could
187 ultimately impede the progression of PCa(Xie et al., 2020). WDPCP, a PCP effector,
188 can regulate PCP by directly modulating the actin cytoskeleton(Cui et al., 2013).

189 Disruption of PCP signaling can cause abnormal cell behavior and tissue structure,
190 leading to the development of cancer(Humphries & Mlodzik, 2018). EEFSEC
191 (eukaryotic elongation factor, selenocysteine-tRNA specific) was identified as a
192 genome-wide significant loci in recent chronic obstructive pulmonary disease
193 GWAS(Hobbs et al., 2017; Wain et al., 2017). TNS3 (Tensin 3) is involved in cell

194 migration, invasion and adhesion processes(Chen et al., 2017; Martuszevska et al.,
195 2009; Zheng et al., 2021; Zuidema et al., 2022), which are critical in cancer
196 metastasis. To certain whether these 4 genes causative factors for PCa, genetic
197 association studies with a larger sample size will be needed.

198 In the cross-phenotype Analysis of PCa, we found that prostate specific antigen (PSA)
199 measurement, BMI-adjusted waist-hip ratio (WHR), high density lipoprotein
200 cholesterol (HDL) measurement, systolic blood pressure, balding measurement and
201 other traits were significantly associated with PCa. These findings highlighted the
202 multifactorial nature of PCa and underscored the importance of considering a broad
203 range of physiological and biochemical factors in understanding its etiology and
204 progression.

205 PSA measurement, a protein secreted by both normal and malignant prostate epithelial
206 cells, has long been a cornerstone in the early detection and monitoring of
207 PCa(Oesterling, 1991). However, the specificity and sensitivity of PSA as a diagnostic
208 tool have been questioned due to its elevation in benign conditions such as prostatitis
209 and benign prostatic hyperplasia, leading to unnecessary biopsies(Carter et al., 2013)
210 and substantial overdiagnosis(Draisma et al., 2009). Therefore, supplementary
211 biomarkers are urgently needed to improve diagnostic accuracy.

212 Obesity has emerged as a significant risk factor in cancer development(Petrelli et al.,
213 2021), such as aggressive PCa(Moyad, 2015). The significant association between
214 BMI-adjusted WHR and PCa suggested that central obesity may play a critical role in
215 the development of PCa(Perez-Cornago, Dunneram, Watts, Key, & Travis, 2022).

216 Central adiposity, primarily referring to visceral adipose tissue, can influence
217 hormone levels and inflammatory processes, thereby contributing to
218 carcinogenesis(Doyle, Donohoe, Lysaght, & Reynolds, 2012). HDL cholesterol is
219 known for its atherosclerotic protective effects(Rohatgi, Westerterp, von Eckardstein,
220 Remaley, & Rye, 2021), mainly due to the ability to promote the reverse transport of
221 cholesterol from peripheral cells to the liver for excretion(Cuchel & Rader, 2006), and
222 to exert antioxidant and anti-inflammatory activities. Through similar mechanisms,
223 HDL may influence the development and progression of tumors, by directly
224 interacting with cancer cells or by modifying the tumor microenvironment(Ossoli,
225 Wolska, Remaley, & Gomaraschi, 2022). Higher HDL levels might confer a
226 protective effect against PCa by influencing cancer cells proliferation, possibly
227 through mechanisms involving antioxidant(Ruscica et al., 2018) and anti-
228 inflammatory properties.

229 Results from previous studies of the association between hypertension and PCa
230 development have been inconsistent(Christakoudi et al., 2020; Liang et al., 2016;
231 Seretis et al., 2019). One MR analysis suggested that elevated systolic blood pressure
232 might be linked to an increased risk of PCa, potentially due to systemic
233 inflammation(Stikbakke et al., 2022), which contributed to a pro-tumorigenic
234 environment by promoting cellular proliferation, DNA damage, and resistance to
235 apoptosis(Mantovani, Allavena, Sica, & Balkwill, 2008). However, the precise
236 relationship between systolic blood pressure and PCa remains unclear. More research
237 is needed to elucidate the exact biological pathways involved and to determine

238 whether managing hypertension could serve as a preventive strategy for PCa.

239 The underlying mechanism for the link between androgenic alopecia and an increased
240 risk of PCa may involve androgen metabolism, as both conditions are influenced by
241 dihydrotestosterone (DHT) levels. Elevated DHT can promote the miniaturization of
242 hair follicle leading to balding(Kaufman, 1996), as well as stimulate prostate cell
243 proliferation(Tong et al., 2022), contributing to the development of PCa. While these
244 associations highlight a potential shared hormonal pathway, further studies are needed
245 to confirm the causality. Overall, our cross-phenotype analysis provided a
246 comprehensive view of the diverse factors associated with PCa and enhanced our
247 understanding of the disease's multifaceted nature. Future researches should focus on
248 elucidating the underlying mechanisms of these associations and exploring their
249 potential for integration into clinical practice.

250 We performed a PW-MR study supplemented by colocalization analysis to explore the
251 casual association of 3,722 plasma proteins with the risk of PCa. MR analysis
252 identified a total of 193 unique proteins significantly associated with PCa, of which
253 10 proteins had a strong support of colocalization. Microseminoprotein-beta
254 (MSMB), also known as PSP94 or beta-inhibin, as an immunoglobulin superfamily
255 protein and one of the most abundant proteins secreted by prostate epithelial cells has
256 the strongest correlation(Byrne et al., 2019). We predicted that men with lower blood
257 levels of MSMB have higher risk of PCa, based on two European ancestry cancer
258 GWAS studies. These results were consistent with another published prospective
259 study(Haiman et al., 2013), supporting a potential protective role of MSMB in the

260 development of PCa. One previous publication reported that the decreased expression
261 of MSMB was both in the tumor (especially in more advanced tumor) and adjacent
262 benign prostate tissue(Bergström, Järemo, Nilsson, Adamo, & Bergh, 2018), which is
263 not in conflict as it may be related to aggressiveness of prostate tumors. Although the
264 mechanism of action of MSMB in PCa is unclear, it has been shown to control
265 prostate cell growth by regulating apoptosis(Garde et al., 1999). In addition to our
266 study, several other studies also supported the potential of MSMB as a serum marker
267 for the early detection of PCa(Nam et al., 2006; Reeves, Dulude, Panchal, Daigneault,
268 & Ramnani, 2006). Consequently, further research is essential to explore the
269 functional role and possible clinical utility of MSMB in PCa.

270 Serine protease inhibitor A3 (SERPINA3), an inhibitors of serine proteases that
271 promotes tumor development by regulating the transcription of some oncogenes and
272 its elevation was associated with a worse prognosis in some cancers(De Mezer et al.,
273 2023). SERPINA3 was up-regulated in PCa cells and enhanced cells migration and
274 invasion(Z. S. Xing, Li, Liu, Zhang, & Bai, 2021), which was consistent with our
275 prediction of it as a risk factor in this MR Study. A study identified that the enhanced
276 expression of SERPINA3 stimulated the bone environment, therefore it may be served
277 as a diagnostic biomarker to predict PCa with bone metastasis phenotype and
278 survival(Ito et al., 2023).

279 Protease serine 3 (PRSS3), also named mesotrypsin, is reported to be aberrantly
280 expressed in various types of tumors and participates in the progression and
281 development of cancers. For example, PRSS3 was identified to be downregulated in

282 lung cancer(Zhou, Li, & Luo, 2023) but upregulated in pancreatic cancer(Jiang et al.,
283 2010; C. J. Xing et al., 2019), suggesting it may have different roles depending on the
284 cellular or disease ways. A study of *vivo* and *vitro* experiments has demonstrated that
285 PRSS3 played an important role in PCa metastasis(Hockla et al., 2012). Despite these
286 findings, further studies are necessary to fully understand the functions and
287 mechanisms of PRSS3 in human PCa.

288 KLK3 (Kallikrein Related Peptidase 3), also known as PSA, is a serine protease
289 predominantly expressed in the prostate gland. One potential mechanism through
290 which KLK3 may influence PCa development involved its proteolytic activity, which
291 can degrade extracellular matrix components and facilitate tumor invasion and
292 metastasis(Avgeris, Mavridis, & Scorilas, 2012; Lawrence, Lai, & Clements, 2010;
293 Mavridis, Avgeris, & Scorilas, 2014). Additionally, the androgen regulation of KLK3
294 expression correlated with the androgen receptor signaling pathway, a critical driver
295 of PCa progression, particularly in castration-resistant prostate cancer (CRPC)(Lilja,
296 Ulmert, & Vickers, 2008). Despite these insights, the precise biological pathways
297 through which KLK3 contributes to PCa progression remain incompletely understood.
298 Further research is needed to illustrate the direct and indirect effects of KLK3 on PCa
299 cells and the tumor microenvironment.

300 Lastly, the druggability evaluation identified 45 protein biomarkers that have been
301 targeted by 128 drugs. Among these, three drugs targeting HSPB1, RRM2B and
302 PSCA, respectively, are currently in clinical trials for potential use in PCa treatment.
303 HSPB1, also known as human HSP27, is a small heat-shock protein that functions as

304 a molecular chaperone, protecting cells against stress-induced damage and
305 apoptosis(Okuno, Adachi, Kozawa, Shimizu, & Yasuda, 2016). It was overexpressed
306 in various cancers(Sheng et al., 2017; Shi et al., 2019), including PCa(Shiota et al.,
307 2013; Vasiljevic et al., 2013), and was associated with tumor progression, metastasis
308 and resistance to therapy. Evidences *in vitro* and *in vivo* suggested that inhibiting
309 HSP27 inhibits tumor growth and sensitivity to cytotoxic chemotherapy(Hadaschik et
310 al., 2008; Kamada et al., 2007). APATORSEN is an antisense oligonucleotide
311 designed to inhibit HSPB1 expression(Jansen & Zangemeister-Wittke, 2002), which
312 is still in clinical trials.

313 RRM2B is a subunit of ribonucleotide reductase, an enzyme critical for DNA
314 synthesis and repair(Okumura et al., 2005). Its expression was upregulated in
315 response to DNA damage and was involved in maintaining genomic stability(Aye, Li,
316 Long, & Weiss, 2015; Foskolou et al., 2017). Elevated levels and distinct mutation
317 signatures of RRM2B have been linked to poor prognosis in several cancers(Iqbal et
318 al., 2021). PSCA is a cell surface glycoprotein highly expressed in high-grade PCa(Gu
319 et al., 2000; Zhigang & Wenlv, 2004) and other solid tumors(Teng et al., 2022), and
320 was involved in cell proliferation, adhesion and survival(Li et al., 2017).

321 This study possessed several strengths, including the use of the largest collection of
322 plasma protein data (covering more than 4800 proteins), large sample sizes of GWAS
323 studies, a mutual validation across two independent outcome datasets and the use of
324 colocalization analysis to support the MR results. Additionally, our assessment of the
325 human blood proteome relied on two technologies (SOMAmer and Olink), which

326 were valuable for identifying plasma proteins associated with diseases traits such as
327 PCa.

328 Some limitations of our analysis should be acknowledged. Firstly, this investigation
329 was only confined to Europeans, restricting the applicability of our findings to other
330 populations. It is crucial for future studies to identify risk proteins in more diverse
331 populations, especially African ancestry who face a higher risk of PCa. Moreover, our
332 study concentrated on the proteins available in the MR analysis, which likely led to
333 the omission of other potential therapeutic targets. Lastly, we utilized proteomic data
334 from Icelanders whose genetic backgrounds may differ from other European
335 populations, which might introduce bias. However, this potential bias might be
336 minimal, as we found that 20 proteins showing significance ($P < 0.05$) in both the
337 deCODE and UKB-PPP studies had consistent associations with PCa.

338 In conclusion, we conducted a large-scale PW-MR study using the MR and
339 colocalization analysis to investigate the genetic associations of up to 3,722 unique
340 proteins with PCa. We revealed the complex genetic architecture of PCa and
341 identified many new plasma proteins with strong causal associations to PCa. These
342 findings highlighted the potential biomarkers for early detection and therapeutic
343 targets, providing a foundation for future research and potential clinical applications.

344 **Methods**

345 **Data sources for plasma proteins**

346 We selected *cis*-SNPs associated with plasma proteins as instrumental variables from
347 two large-scale GWASs in the deCODE Genetics(Ferkingstad et al., 2021) and UKB-
348 PPP(Sun et al., 2023). *Cis*-SNPs were defined as SNPs within a vicinity of ± 1 Mb
349 around the gene encoding the protein. From these SNPs, only those with a minor
350 allele frequency of $\geq 1\%$ that were genome-wide significance ($p < 5 \times 10^{-8}$) and
351 considered independent (linkage disequilibrium $r^2 < 0.1$ in 1000G) were retained.
352 deCODE Genetics conducted proteomic profiling on blood plasma samples from
353 35,559 Icelanders using the SomaScan platform and collected data on 4907
354 aptamers(Ferkingstad et al., 2021). For the two-sample MR analysis, we selected *cis*-
355 SNPs as instrumental variables for 1778 proteins. Likewise, *cis*-SNPs for 1944
356 plasma proteins were obtained from the UKB-PPP where 2940 proteins were
357 measured among 54,219 Europeans using the Olink platform(Sun et al., 2023). The
358 proteins with positive MR results were included in the colocalization analysis.

359 **Data sources for Prostate Cancer**

360 GWAS summary statistics for PCa were obtained from the PRACTICAL
361 consortium(Schumacher et al., 2018) and FinnGen study. The PRACTICAL (Prostate
362 Cancer Association Group to Investigate Cancer Associated Alterations in the
363 Genome) consortium included 79,198 cases and 61,106 controls. We used the data on
364 PCa from the FinnGen study R10 in this analysis, which comprised 15,199 cases and
365 131,266 controls. All participants of these two cohorts were of European ancestry. In

366 the MR analysis, we treated the PRACTICAL consortium as the discovery study and
367 the FinnGen R10 study as the replication. To increase the effectiveness, we performed
368 a fixed-effect GWAS meta-analysis of the two GWASs using the METAL package.
369 The quantile-quantile plot was generated using the “qqman” package in R software.
370 The R package “gassocplot” was used to plot regional association plots for the top
371 SNP at each of the genome-wide significant loci identified.

372 **Cross-phenotype analysis**

373 Through the interactive Cross-Phenotype Analysis of GWAS database (iCPAGdb)(L.
374 Wang et al., 2020), a new platform for cross-phenotype analysis, we explored the
375 genetic correlation between PCa and other traits. We analyzed the genetic correlations
376 between PCa and 3793 traits using data from the National Human Genome Research
377 Institute-European Bioinformatics Institute (NHGRI-EBI) GWAS catalog(L. Wang et
378 al., 2020). Through the use of ancestry LD-specific association data, iCPAGdb
379 performs cross-phenotype enrichment analyses. iCPAGdb reveals signals of pairwise
380 traits and shared signals by analyzing traits associations with LD proxy SNPs. The
381 output data will show results from Fisher’s exact test with adjustment for 5% false
382 discovery rate (FDR) and also Bonferroni’s, Jaccard’s, Sorensen’s, and Chao-
383 Sorensen similarity indexes.

384 **MR analysis**

385 We conducted a MR analysis with plasma proteins as the exposure variable and PC as
386 the outcome variable. We utilized the R package “TwoSampleMR” in R software
387 (4.3.3) for the MR analysis. When only one SNP was available for a particular

388 protein, we applied the Wald ratio test. Inverse-variance weighted (IVW) was used as
389 the main analysis method for two or more SNPs available. Considering multiple
390 testing, we employed the 5% False Discovery Rate (FDR) method for P-value
391 correction. $P < 0.05$ was considered statistically significant. MR-Egger and weighted
392 median methods were used as supplementary analysis methods. Cochran's Q statistic
393 test using the MR-Egger method was used to determine the heterogeneity between the
394 genetic variants. We also performed MR-Egger regression intercept to detect and
395 adjust the directional horizontal pleiotropy (Hemani, Bowden, & Smith, 2018), $P < 0.05$
396 was considered as the presence of directional pleiotropy and thus removed from the
397 further analyses.

398 **Colocalization analysis**

399 The "coloc" package was used to perform Bayesian colocalization analysis to
400 investigate if the associations between plasma proteins and PCa were driven by
401 linkage disequilibrium (LD) (Giambartolomei et al., 2014). For proteins with positive
402 MR results, the Bayesian method assessed the support for the following five exclusive
403 hypotheses: 1) no association with either trait; 2) association with trait 1 only; 3)
404 association with trait 2 only; 4) both traits are associated, but distinct causal variants
405 were for two traits; and 5) both traits are associated, and the same shares causal
406 variant for both traits (Foley et al., 2021). The posterior probability is provided for
407 each hypothesis (H0, H1, H2, H3, and H4). In this analysis, we set prior probabilities
408 of the SNP being associated with trait 1 only (p_1) at 1×10^{-4} ; the probability of the
409 SNP being associated with trait 2 only (p_2) at 1×10^{-4} ; and the probability of the SNP

410 being associated with both traits (p_{12}) at 1×10^{-5} . Two signals were considered to
411 have strong evidence of colocalization if the posterior probability for shared causal
412 variants (PH4) was ≥ 0.8 . The analysis was performed in R software (4.3.3).

413 **Biological pathway analysis**

414 The GENE2FUNC tool in FUMA(Watanabe, Taskesen, van Bochoven, & Posthuma,
415 2017) web application programming interface version 1.5.2 were used to investigate
416 functional annotation and enrichment analysis of the genes coding for the 193 unique
417 proteins identified by the PW-MR approach. This analysis involved calculating the
418 log₂ fold-change expression for each gene across 54 tissue types from the GTEx
419 (Genotype-Tissue Expression) database. We conducted gene enrichment analysis to
420 identify overrepresented biological processes using the Gene Ontology (GO)
421 database, which helped determine the biological processes most relevant to the genes
422 identified. To investigate the involvement of the identified genes in functional and
423 signaling pathways, we used the KEGG (Kyoto Encyclopedia of Genes and Genomes)
424 pathway database. Enrichment results were considered significant if they passed 5%
425 FDR P-value threshold. Additionally, only enrichments involving at least two
426 overlapping genes with the gene sets were considered to ensure robustness and
427 biological relevance.

428 **Druggability evaluation**

429 The analysis of drug targets for the significant proteins identified in the MR Analysis
430 was conducted using data from OpenTargets(Ochoa et al., 2023) (v.22.11), which is
431 publicly accessible. We selected all drugs for which there was evidence for an

432 association with the protein of interest.

433 **Data availability**

434 The GWAS summary statistics of blood pQTLs from deCODE can be found at
435 <https://www.decode.com/summarydata/>, and those of the UKB-PPP can be found at
436 <https://www.synapse.org/#!/Synapse:syn51365303>. Summary statistics of PCa from
437 the PRACTICAL consortium can be obtained from OpenGWAS
438 (<https://gwas.mrcieu.ac.uk/>), and those of the FinnGen study can be obtained from
439 <https://r10.finnngen.fi/>. The OpenTargets data were downloaded directly from the
440 OpenTargets website (<https://platform.opentargets.org/downloads/data>).

441 **Acknowledgements**

442 The authors would like to thank all the participants and investigators of the studies
443 (PRACTICAL, FinnGen, deCODE, UKB-PPP) for providing the invaluable data used
444 in this research. Their commitment and effort have been essential for the success of
445 this study. Furthermore, special thanks to our colleagues and collaborators for their
446 insightful discussions and feedback throughout the research process. This research
447 was funded by Beijing Municipal Natural Science Foundation (grant No. JQ24059,
448 No. L234038), and National Natural Science Foundation of China (grant No.
449 82274015).

450 **References**

- 451 Avgeris, M., Mavridis, K., & Scorilas, A. (2012). Kallikrein-related peptidases in
452 prostate, breast, and ovarian cancers: from pathobiology to clinical relevance.
453 *Biol Chem*, 393(5), 301-317. doi:10.1515/hsz-2011-0260
- 454 Aye, Y., Li, M., Long, M. J. C., & Weiss, R. S. (2015). Ribonucleotide reductase and
455 cancer: biological mechanisms and targeted therapies. *Oncogene*, 34(16),
456 2011-2021. doi:10.1038/onc.2014.155
- 457 Bergström, S. H., Järemo, H., Nilsson, M., Adamo, H. H., & Bergh, A. (2018).
458 Prostate tumors downregulate microseminoprotein-beta (MSMB) in the
459 surrounding benign prostate epithelium and this response is associated with
460 tumor aggressiveness. *Prostate*, 78(4), 257-265. doi:10.1002/pros.23466
- 461 Byrne, K. S., Appleby, P. N., Key, T. J., Holmes, M. V., Fensom, G. K., Agudo, A., . . .
462 Consortium, P. (2019). The role of plasma microseminoprotein-beta in prostate
463 cancer: an observational nested case-control and Mendelian randomization
464 study in the European prospective investigation into cancer and nutrition.
465 *Annals of Oncology*, 30(6), 983-989. doi:10.1093/annonc/mdz121
- 466 Cao, Y., Nimptsch, K., Shui, I. M., Platz, E. A., Wu, K., Pollak, M. N., . . .
467 Giovannucci, E. L. (2015). Prediagnostic plasma IGFBP-1, IGF-1 and risk of
468 prostate cancer. *International Journal of Cancer*, 136(10), 2418-2426.
469 doi:10.1002/ijc.29295
- 470 Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K.
471 L., . . . Zietman, A. L. (2013). Early Detection of Prostate Cancer: AUA
472 Guideline. *Journal of Urology*, 190(2), 419-426.
473 doi:10.1016/j.juro.2013.04.119
- 474 Chen, H. Y., Lin, L. T., Wang, M. L., Laurent, B., Hsu, C. H., Pan, C. M., . . . Chiou,
475 S. H. (2017). Musashi-1 Enhances Glioblastoma Cell Migration and
476 Cytoskeletal Dynamics through Translational Inhibition of Tensin3. *Scientific*
477 *Reports*, 7, 14. doi:10.1038/s41598-017-09504-7
- 478 Christakoudi, S., Kakourou, A., Markozannes, G., Tzoulaki, I., Weiderpass, E.,

- 479 Brennan, P., . . . Tsilidis, K. K. (2020). Blood pressure and risk of cancer in the
480 European Prospective Investigation into Cancer and Nutrition. *Int J Cancer*,
481 *146*(10), 2680-2693. doi:10.1002/ijc.32576
- 482 Cuchel, M., & Rader, D. J. (2006). Macrophage reverse cholesterol transport: key to
483 the regression of atherosclerosis? *Circulation*, *113*(21), 2548-2555.
484 doi:10.1161/circulationaha.104.475715
- 485 Cui, C., Chatterjee, B., Lozito, T. P., Zhang, Z., Francis, R. J., Yagi, H., . . . Lo, C. W.
486 (2013). Wdpcp, a PCP Protein Required for Ciliogenesis, Regulates
487 Directional Cell Migration and Cell Polarity by Direct Modulation of the Actin
488 Cytoskeleton. *Plos Biology*, *11*(11), 17. doi:10.1371/journal.pbio.1001720
- 489 Davies, N. M., Holmes, M. V., & Smith, G. D. (2018). Reading Mendelian
490 randomisation studies: a guide, glossary, and checklist for clinicians. *Bmj-*
491 *British Medical Journal*, *362*, 11. doi:10.1136/bmj.k601
- 492 De Mezer, M., Rogalinski, J., Przewozny, S., Chojnicki, M., Niepolski, L., Sobieska,
493 M., & Przystanska, A. (2023). SERPINA3: Stimulator or Inhibitor of
494 Pathological Changes. *Biomedicines*, *11*(1), 15.
495 doi:10.3390/biomedicines11010156
- 496 Deichaite, I., Sears, T. J., Sutton, L., Rebibo, D., Morgan, K., Nelson, T., . . . Carter,
497 H. (2022). Differential regulation of TNF α and IL-6 expression contributes to
498 immune evasion in prostate cancer. *Journal of Translational Medicine*, *20*(1),
499 16. doi:10.1186/s12967-022-03731-x
- 500 Doyle, S. L., Donohoe, C. L., Lysaght, J., & Reynolds, J. V. (2012). Visceral obesity,
501 metabolic syndrome, insulin resistance and cancer. *Proc Nutr Soc*, *71*(1), 181-
502 189. doi:10.1017/s002966511100320x
- 503 Draisma, G., Etzioni, R., Tsodikov, A., Mariotto, A., Wever, E., Gulati, R., . . . de
504 Koning, H. (2009). Lead Time and Overdiagnosis in Prostate-Specific Antigen
505 Screening: Importance of Methods and Context. *Jnci-Journal of the National*
506 *Cancer Institute*, *101*(6), 374-383. doi:10.1093/jnci/djp001
- 507 Ferkingstad, E., Sulem, P., Atlason, B. A., Sveinbjornsson, G., Magnusson, M. I.,
508 Styrismisdottir, E. L., . . . Stefansson, K. (2021). Large-scale integration of the

- 509 plasma proteome with genetics and disease. *Nature Genetics*, 53(12), 1712-+.
510 doi:10.1038/s41588-021-00978-w
- 511 Ferlay J, E. M., Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A,
512 Soerjomataram I, Bray F . (2024). Global Cancer Observatory: Cancer Today.
513 Retrieved from <https://gco.iarc.who.int/today>
- 514 Foley, C. N., Staley, J. R., Breen, P. G., Sun, B. B., Kirk, P. D. W., Burgess, S., &
515 Howson, J. M. M. (2021). A fast and efficient colocalization algorithm for
516 identifying shared genetic risk factors across multiple traits. *Nature*
517 *Communications*, 12(1), 18. doi:10.1038/s41467-020-20885-8
- 518 Foskolou, I. P., Jorgensen, C., Leszczynska, K. B., Olcina, M. M., Tarhonskaya, H.,
519 Haisma, B., . . . Hammond, E. M. (2017). Ribonucleotide Reductase Requires
520 Subunit Switching in Hypoxia to Maintain DNA Replication. *Molecular Cell*,
521 66(2), 206-+. doi:10.1016/j.molcel.2017.03.005
- 522 Frayling, T. M., Colhoun, H., & Florez, J. C. (2008). A genetic link between type 2
523 diabetes and prostate cancer - Commentary. *Diabetologia*, 51(10), 1757-1760.
524 doi:10.1007/s00125-008-1114-9
- 525 Garde, S. V., Basrur, V. S., Li, L., Finkelman, M. A., Krishan, A., Wellham, L., . . .
526 Tang, D. G. (1999). Prostate secretory protein (PSP94) suppresses the growth
527 of androgen-independent prostate cancer cell line (PC3) and xenografts by
528 inducing apoptosis. *Prostate*, 38(2), 118-125. doi:10.1002/(sici)1097-
529 0045(19990201)38:2<118::Aid-pros5>3.0.Co;2-g
- 530 Giambartolomei, C., Vukcevic, D., Schadt, E. E., Franke, L., Hingorani, A. D.,
531 Wallace, C., & Plagnol, V. (2014). Bayesian Test for Colocalisation between
532 Pairs of Genetic Association Studies Using Summary Statistics. *Plos Genetics*,
533 10(5), 15. doi:10.1371/journal.pgen.1004383
- 534 Gu, Z., Thomas, G., Yamashiro, J., Shintaku, I. P., Dorey, F., Raitano, A., . . . Reiter,
535 R. E. (2000). Prostate stem cell antigen (PSCA) expression increases with high
536 gleason score, advanced stage and bone metastasis in prostate cancer.
537 *Oncogene*, 19(10), 1288-1296. doi:10.1038/sj.onc.1203426
- 538 Hadaschik, B. A., Jackson, J., Fazli, L., Zoubeydi, A., Burt, H. M., Gleave, M. E., &

- 539 So, A. I. (2008). Intravesically administered antisense oligonucleotides
540 targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive
541 bladder cancer. *Bju International*, *102*(5), 610-616. doi:10.1111/j.1464-
542 410X.2008.07669.x
- 543 Haiman, C. A., Stram, D. O., Vickers, A. J., Wilkens, L. R., Braun, K., Valtonen-
544 André, C., . . . Lilja, H. (2013). Levels of Beta-Microseminoprotein in Blood
545 and Risk of Prostate Cancer in Multiple Populations. *Jnci-Journal of the*
546 *National Cancer Institute*, *105*(3), 237-243. doi:10.1093/jnci/djs486
- 547 Hemani, G., Bowden, J., & Smith, G. D. (2018). Evaluating the potential role of
548 pleiotropy in Mendelian randomization studies. *Human Molecular Genetics*,
549 *27*(R2), R195-R208. doi:10.1093/hmg/ddy163
- 550 Hobbs, B. D., de Jong, K., Lamontagne, M., Bossé, Y., Shrine, N., Artigas, M. S., . . .
551 Int, C. G. C. (2017). Genetic loci associated with chronic obstructive
552 pulmonary disease overlap with loci for lung function and pulmonary fibrosis.
553 *Nature Genetics*, *49*(3), 426-432. doi:10.1038/ng.3752
- 554 Hockla, A., Miller, E., Salameh, M. A., Copland, J. A., Radisky, D. C., & Radisky, E.
555 S. (2012). PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate
556 Cancer. *Molecular Cancer Research*, *10*(12), 1555-1566. doi:10.1158/1541-
557 7786.Mcr-12-0314
- 558 Humphries, A. C., & Mlodzik, M. (2018). From instruction to output: Wnt/PCP
559 signaling in development and cancer. *Current Opinion in Cell Biology*, *51*,
560 110-116. doi:10.1016/j.ceb.2017.12.005
- 561 Iqbal, W., Demidova, E. V., Serrao, S., ValizadehAslani, T., Rosen, G., & Arora, S.
562 (2021). RRM2B Is Frequently Amplified Across Multiple Tumor Types:
563 Implications for DNA Repair, Cellular Survival, and Cancer Therapy.
564 *Frontiers in Genetics*, *12*, 13. doi:10.3389/fgene.2021.628758
- 565 Ito, K., Yamamoto, T., Hayashi, Y., Sato, S., Nakayama, J., Urabe, F., . . . Yamamoto,
566 Y. (2023). Osteoblast-derived extracellular vesicles exert osteoblastic and
567 tumor-suppressive functions via SERPINA3 and LCN2 in prostate cancer.
568 *Molecular Oncology*, *17*(10), 2147-2167. doi:10.1002/1878-0261.13484

- 569 James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., . . . Xie, L.-P.
570 (2024). The Lancet Commission on prostate cancer: planning for the surge in
571 cases. *Lancet (London, England)*, *403*(10437), 1683-1722. doi:10.1016/s0140-
572 6736(24)00651-2
- 573 Jansen, B., & Zangemeister-Wittke, U. (2002). Antisense therapy for cancer - the time
574 of truth. *Lancet Oncology*, *3*(11), 672-683. doi:10.1016/s1470-2045(02)00903-
575 8
- 576 Jiang, G. Z., Cao, F. Y., Ren, G. P., Gao, D. L., Bhakta, V., Zhang, Y. H., . . . Wang, Y.
577 H. (2010). PRSS3 promotes tumour growth and metastasis of human
578 pancreatic cancer. *Gut*, *59*(11), 1535-1544. doi:10.1136/gut.2009.200105
- 579 Kamada, M., So, A., Muramaki, M., Rocchi, P., Beraldi, E., & Gleave, M. (2007).
580 Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and
581 enhance chemotherapy in human bladder cancer cells. *Molecular Cancer*
582 *Therapeutics*, *6*(1), 299-308. doi:10.1158/1535-7163.Mct-06-0417
- 583 Kaufman, K. D. (1996). Androgen metabolism as it affects hair growth in
584 androgenetic alopecia. *Dermatol Clin*, *14*(4), 697-711. doi:10.1016/s0733-
585 8635(05)70396-x
- 586 Lawrence, M. G., Lai, J., & Clements, J. A. (2010). Kallikreins on steroids: structure,
587 function, and hormonal regulation of prostate-specific antigen and the
588 extended kallikrein locus. *Endocr Rev*, *31*(4), 407-446. doi:10.1210/er.2009-
589 0034
- 590 Li, E. M., Liu, L. H., Li, F. T., Luo, L. M., Zhao, S. K., Wang, J. M., . . . Zhao, Z. G.
591 (2017). PSCA promotes prostate cancer proliferation and cell-cycle
592 progression by up-regulating c-Myc. *Prostate*, *77*(16), 1563-1572.
593 doi:10.1002/pros.23432
- 594 Liang, Z., Xie, B., Li, J., Wang, X., Wang, S., Meng, S., . . . Xie, L. (2016).
595 Hypertension and risk of prostate cancer: a systematic review and meta-
596 analysis. *Scientific Reports*, *6*, 31358. doi:10.1038/srep31358
- 597 Lilja, H., Ulmert, D., & Vickers, A. J. (2008). Prostate-specific antigen and prostate
598 cancer: prediction, detection and monitoring. *Nat Rev Cancer*, *8*(4), 268-278.

- 599 doi:10.1038/nrc2351
- 600 Machiela, M. J., Lindström, S., Allen, N. E., Haiman, C. A., Albanes, D., Barricarte,
601 A., . . . Kraft, P. (2012). Association of Type 2 Diabetes Susceptibility Variants
602 With Advanced Prostate Cancer Risk in the Breast and Prostate Cancer Cohort
603 Consortium. *American Journal of Epidemiology*, 176(12), 1121-1129.
604 doi:10.1093/aje/kws191
- 605 Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related
606 inflammation. *Nature*, 454(7203), 436-444. doi:10.1038/nature07205
- 607 Martuszezka, D., Ljungberg, B., Johansson, M., Landberg, G., Oslakovic, C.,
608 Dahlbäck, B., & Hafizi, S. (2009). Tensin3 Is a Negative Regulator of Cell
609 Migration and All Four Tensin Family Members Are Downregulated in
610 Human Kidney Cancer. *Plos One*, 4(2), 13. doi:10.1371/journal.pone.0004350
- 611 Mavridis, K., Avgeris, M., & Scorilas, A. (2014). Targeting kallikrein-related
612 peptidases in prostate cancer. *Expert Opin Ther Targets*, 18(4), 365-383.
613 doi:10.1517/14728222.2014.880693
- 614 Moyad, M. A. (2015). Preventing aggressive prostate cancer with proven
615 cardiovascular disease preventive methods. *Asian J Androl*, 17(6), 874-877;
616 discussion 876. doi:10.4103/1008-682x.156854
- 617 Nakajima, T., Fujino, S., Nakanishi, G., Kim, Y. S., & Jetten, A. M. (2004). TIP27: a
618 novel repressor of the nuclear orphan receptor TAK1/TR4. *Nucleic Acids
619 Research*, 32(14), 4194-4204. doi:10.1093/nar/gkh741
- 620 Nam, R. K., Reeves, J. R., Toi, A., Dulude, H., Trachtenberg, J., Emami, M., . . .
621 Narod, S. A. (2006). A novel serum marker, total prostate secretory protein of
622 94 amino acids, improves prostate cancer detection and helps identify high
623 grade cancers at diagnosis. *Journal of Urology*, 175(4), 1291-1297.
624 doi:10.1016/s0022-5347(05)00695-6
- 625 Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Baker, J., Malangone, C., . . .
626 McDonagh, E. (2023). The next-generation Open Targets Platform:
627 reimaged, redesigned, rebuilt. *Nucleic Acids Research*, 51(D1), D1353-
628 D1359. doi:10.1093/nar/gkac1046

- 629 Oesterling, J. E. (1991). PROSTATE SPECIFIC ANTIGEN - A CRITICAL-
630 ASSESSMENT OF THE MOST USEFUL TUMOR-MARKER FOR
631 ADENOCARCINOMA OF THE PROSTATE. *Journal of Urology*, *145*(5),
632 907-923. doi:10.1016/s0022-5347(17)38491-4
- 633 Okumura, H., Natsugoe, S., Matsumoto, M., Mataka, Y., Takatori, H., Ishigami, S., . . .
634 Aikou, T. (2005). The predictive value of p53, p53R2, and p21 for the effect of
635 chemoradiation therapy on oesophageal squamous cell carcinoma. *British*
636 *Journal of Cancer*, *92*(2), 284-289. doi:10.1038/sj.bjc.6602322
- 637 Okuno, M., Adachi, S., Kozawa, O., Shimizu, M., & Yasuda, I. (2016). The Clinical
638 Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic
639 Cancer. *International Journal of Molecular Sciences*, *17*(1), 7.
640 doi:10.3390/ijms17010137
- 641 Ossoli, A., Wolska, A., Remaley, A. T., & Gomaschi, M. (2022). High-density
642 lipoproteins: A promising tool against cancer. *Biochim Biophys Acta Mol Cell*
643 *Biol Lipids*, *1867*(1), 159068. doi:10.1016/j.bbalip.2021.159068
- 644 Perez-Cornago, A., Dunneram, Y., Watts, E. L., Key, T. J., & Travis, R. C. (2022).
645 Adiposity and risk of prostate cancer death: a prospective analysis in UK
646 Biobank and meta-analysis of published studies. *Bmc Medicine*, *20*(1), 13.
647 doi:10.1186/s12916-022-02336-x
- 648 Petrelli, F., Cortellini, A., Indini, A., Tomasello, G., Ghidini, M., Nigro, O., . . .
649 Zaniboni, A. (2021). Association of Obesity With Survival Outcomes in
650 Patients With Cancer A Systematic Review and Meta-analysis. *Jama Network*
651 *Open*, *4*(3), 30. doi:10.1001/jamanetworkopen.2021.3520
- 652 Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Cortes, A., Koprulu, M., Wörheide, M.
653 A., . . . Langenberg, C. (2021). Mapping the proteo-genomic convergence of
654 human diseases. *Science*, *374*(6569), 839-+. doi:10.1126/science.abj1541
- 655 Reeves, J. R., Dulude, H., Panchal, C., Daigneault, L., & Ramnani, D. M. (2006).
656 Prognostic value of prostate secretory protein of 94 amino acids and its
657 binding protein after radical prostatectomy. *Clinical Cancer Research*, *12*(20),
658 6018-6022. doi:10.1158/1078-0432.Ccr-06-0625

- 659 Rohatgi, A., Westerterp, M., von Eckardstein, A., Remaley, A., & Rye, K. A. (2021).
660 HDL in the 21st Century: A Multifunctional Roadmap for Future HDL
661 Research. *Circulation*, *143*(23), 2293-2309.
662 doi:10.1161/circulationaha.120.044221
- 663 Rosario, S. R., Jacobi, J. J., Long, M. D., Affronti, H. C., Rowsam, A. M., &
664 Smiraglia, D. J. (2023). JAZF1: A Metabolic Regulator of Sensitivity to a
665 Polyamine-Targeted Therapy. *Molecular Cancer Research*, *21*(1), 24-35.
666 doi:10.1158/1541-7786.Mcr-22-0316
- 667 Ruscica, M., Botta, M., Ferri, N., Giorgio, E., Macchi, C., Franceschini, G., . . .
668 Gomaraschi, M. (2018). High Density Lipoproteins Inhibit Oxidative Stress-
669 Induced Prostate Cancer Cell Proliferation. *Scientific Reports*, *8*(1), 2236.
670 doi:10.1038/s41598-018-19568-8
- 671 Saxena, R., Voight, B. F., Zeggini, E., Scott, L. J., & Genetics, I. C. D. (2008). Meta-
672 analysis of genome-wide association data and large-scale replication identifies
673 several additional susceptibility loci for type 2 diabetes. *Diabetes*, *57*, A41-
674 A41. Retrieved from <Go to ISI>://WOS:000256612000133
- 675 Schumacher, F. R., Al Olama, A. A., Berndt, S. I., Benlloch, S., Ahmed, M., Saunders,
676 E. J., . . . Elucidating Loci Involved, P. (2018). Association analyses of more
677 than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nature*
678 *Genetics*, *51*(2), 363-363. doi:10.1038/s41588-018-0330-6
- 679 Seretis, A., Cividini, S., Markozannes, G., Tseretopoulou, X., Lopez, D. S., Ntzani, E.
680 E., & Tsilidis, K. K. (2019). Association between blood pressure and risk of
681 cancer development: a systematic review and meta-analysis of observational
682 studies. *Scientific Reports*, *9*(1), 8565. doi:10.1038/s41598-019-45014-4
- 683 Sheng, B. W., Qi, C. C., Liu, B., Lin, Y., Fu, T., & Zeng, Q. D. (2017). Increased
684 HSP27 correlates with malignant biological behavior of non-small cell lung
685 cancer and predicts patient's survival. *Scientific Reports*, *7*, 12.
686 doi:10.1038/s41598-017-13956-2
- 687 Shi, D. B., Ma, R. R., Zhang, H., Hou, F., Guo, X. Y., & Gao, P. (2019). GAGE7B
688 promotes tumor metastasis and growth via activating the

- 689 p38/pMAPKAPK2/pHSP27 pathway in gastric cancer. *Journal of*
690 *Experimental & Clinical Cancer Research*, 38, 12. doi:10.1186/s13046-019-
691 1125-z
- 692 Shiota, M., Bishop, J. L., Nip, K. M., Zardan, A., Takeuchi, A., Cordonnier, T., . . .
693 Zoubeidi, A. (2013). Hsp27 Regulates Epithelial Mesenchymal Transition,
694 Metastasis, and Circulating Tumor Cells in Prostate Cancer. *Cancer Research*,
695 73(10), 3109-3119. doi:10.1158/0008-5472.Can-12-3979
- 696 Stikbakke, E., Schirmer, H., Knutsen, T., Støyten, M., Wilsgaard, T., Giovannucci, E.
697 L., . . . Thune, I. (2022). Systolic and diastolic blood pressure, prostate cancer
698 risk, treatment, and survival. The PROCA-life study. *Cancer Med*, 11(4),
699 1005-1015. doi:10.1002/cam4.4523
- 700 Sun, B. B., Chiou, J., Traylor, M., Benner, C., Hsu, Y. H., Richardson, T. G., . . .
701 Whelan, C. D. (2023). Plasma proteomic associations with genetics and health
702 in the UK Biobank. *Nature*, 622(7982), 329-338. doi:10.1038/s41586-023-
703 06592-6
- 704 Sung, Y., Park, S., Park, S. J., Jeong, J., Choi, M., Lee, J., . . . Kim, M. O. (2018).
705 Jazfl promotes prostate cancer progression by activating JNK/Slug.
706 *Oncotarget*, 9(1), 755-765. doi:10.18632/oncotarget.23146
- 707 Teng, K. Y., Mansour, A. G., Zhu, Z., Li, Z. Y., Tian, L., Ma, S. B., . . . Yu, J. H.
708 (2022). Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen
709 Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer.
710 *Gastroenterology*, 162(4), 1319-1333. doi:10.1053/j.gastro.2021.12.281
- 711 Thomas, G., Jacobs, K. B., Yeager, M., Kraft, P., Wacholder, S., Orr, N., . . . Chanock,
712 S. J. (2008). Multiple loci identified in a genome-wide association study of
713 prostate cancer. *Nature Genetics*, 40(3), 310-315. doi:10.1038/ng.91
- 714 Tong, Y., Guo, Y. J., Zhang, Q., Bi, H. X., Kai, K., & Zhou, R. Y. (2022). Combined
715 treatment with dihydrotestosterone and lipopolysaccharide modulates prostate
716 homeostasis by upregulating TNF- α from M1 macrophages and promotes
717 proliferation of prostate stromal cells. *Asian J Androl*, 24(5), 513-520.
718 doi:10.4103/aja2021114

- 719 Vasiljevic, N., Ahmad, A. S., Beesley, C., Thorat, M. A., Fisher, G., Berney, D.
720 M., . . . Lorincz, A. T. (2013). Association between DNA methylation of
721 *HSPB1* and death in low Gleason score prostate cancer. *Prostate*
722 *Cancer and Prostatic Diseases*, 16(1), 35-40. doi:10.1038/pcan.2012.47
- 723 Wain, L. V., Shrine, N., Artigas, M. S., Erzurumluoglu, A. M., Noyvert, B., Bossini-
724 Castillo, L., . . . Geisinger-Regeneron Discov, E. H. R. (2017). Genome-wide
725 association analyses for lung function and chronic obstructive pulmonary
726 disease identify new loci and potential druggable targets. *Nature Genetics*,
727 49(3), 416-425. doi:10.1038/ng.3787
- 728 Wang, L., Balmat, T. J., Antonia, A. L., Constantine, F. J., Henao, R., Burke, T.
729 W., . . . Ko, D. C. (2020). An atlas connecting shared genetic architecture of
730 human diseases and molecular phenotypes provides insight into COVID-19
731 susceptibility. *medRxiv : the preprint server for health sciences*.
732 doi:10.1101/2020.12.20.20248572
- 733 Wang, X. J., & Su, H. B. (2010). Unraveling Enigma in the Z-Disk. *Circulation*
734 *Research*, 107(3), 321-323. doi:10.1161/circresaha.110.225615
- 735 Watanabe, K., Taskesen, E., van Bochoven, A., & Posthuma, D. (2017). Functional
736 mapping and annotation of genetic associations with FUMA. *Nature*
737 *Communications*, 8, 11. doi:10.1038/s41467-017-01261-5
- 738 Xie, P. B., Liu, M. S., Chen, F., Wu, S. M., Shao, T., Wang, W., . . . Zhou, H. Q.
739 (2020). Long Non-coding RNA AGAP2-AS1 Silencing Inhibits PDLIM5
740 Expression Impeding Prostate Cancer Progression*via* Up-Regulation of
741 MicroRNA-195-5p. *Frontiers in Genetics*, 11, 13.
742 doi:10.3389/fgene.2020.01030
- 743 Xing, C. J., Ye, H., Wang, W. W., Sun, M. M., Zhang, J. Y., Zhao, Z. H., & Jiang, G.
744 Z. (2019). Circular RNA ADAM9 facilitates the malignant behaviours of
745 pancreatic cancer by sponging miR-217 and upregulating PRSS3 expression.
746 *Artificial Cells Nanomedicine and Biotechnology*, 47(1), 3920-3928.
747 doi:10.1080/21691401.2019.1671856
- 748 Xing, Z. S., Li, S. L., Liu, Z. X., Zhang, C., & Bai, Z. M. (2021). CircSERPINA3

749 regulates SERPINA3-mediated apoptosis, autophagy and aerobic glycolysis of
750 prostate cancer cells by competitively binding to MiR-653-5p and recruiting
751 BUD13. *Journal of Translational Medicine*, 19(1), 13. doi:10.1186/s12967-
752 021-03063-2


753 Zheng, J. Y., Wang, C. Y., Gao, C., Xiao, Q., Huang, C. W., Wu, M., & Li, L. Y.
754 (2021). MLL3 suppresses tumorigenesis through regulating TNS3 enhancer
755 activity. *Cell Death & Disease*, 12(4), 13. doi:10.1038/s41419-021-03647-2

756 Zhigang, Z., & Wenlv, S. (2004). Prostate stem cell antigen (PSCA) expression in
757 human prostate cancer tissues and its potential role in prostate carcinogenesis
758 and progression of prostate cancer. *World journal of surgical oncology*, 2, 13.
759 doi:10.1186/1477-7819-2-13

760 Zhou, M. Y., Li, K. K., & Luo, K. Q. (2023). Shear Stress Drives the Cleavage
761 Activation of Protease-Activated Receptor 2 by PRSS3/Mesotrypsin to
762 Promote Invasion and Metastasis of Circulating Lung Cancer Cells. *Advanced
763 Science*, 10(25), 21. doi:10.1002/advs.202301059

764 Zuidema, A., Atherton, P., Kreft, M., Hoekman, L., Bleijerveld, O. B., Nagaraj,
765 N., . . . Sonnenberg, A. (2022). PEAK1 Y635 phosphorylation regulates cell
766 migration through association with Tensin3 and integrins. *Journal of Cell
767 Biology*, 221(8), 18. doi:10.1083/jcb.202108027

Graphical abstract:






Figure 1. Manhattan plot of PCa GWAS meta-analysis. The genetic regions containing top SNPs related to PCa are depicted. The red dashed line signifies the genome-wide significance threshold of 5.0×10^{-8} .




Figure 2. The top 10 significant cross-phenotype associations with PCa at a 5% FDR. The x-axis represents the P value of the correlation. BMI, body mass index.




Figure 4. Colocalization plot of SERPINA3 variants associated with PCa in deCODE and UKB-PPP. Variants are color-coded based on their linkage disequilibrium (LD) with the lead SNP (the variant with the lowest p-value). The lead SNP is highlighted in red. Other variants are colored from blue to yellow, indicating decreasing LD with the lead SNP.




Figure 5. Functional annotation of the genetic architecture of PCa. (A) Biological processes and (B) KEGG pathway analysis of the 193 unique proteins identified in deCODE and UKB-PPP.